Epilepsy with Myoclonic Absences – Favourable Response to Add-on Rufinamide Treatment in 3 Cases

Abstract

Background: Epilepsy with myoclonic absences (EMA) is a rare epileptic syndrome with frequently poor response to antiepileptic treatment. Rufinamide (RUF) is a relatively new EMEA- and FDA-approved anticonvulsant licensed as an orphan drug for the adjunctive treatment of patients with Lennox-Gastaut syndrome.

Methods: A retrospective data analysis in 3 patients was performed.

Results: Add-on RUF treatment was initiated in 3 boys with EMA refractory to conventional antiepileptic therapy (primidone + valproic acid, n=1; levetiracetame + ethosuximide, n=2). It resulted in complete cessation of all seizures in 2, and a 50% reduction of the seizure frequency in one child, respectively.

Conclusions: RUF add-on therapy should be considered in children with EMA not responding to conventional antiepileptic therapy.

Key words

epilepsy - myoclonic absences - rufinamide

References

• 1 Arroyo S. Rufinamide.  Neurotherapeutics. 2007;  4 155-162
• 2 Berg AT, Berkovic SF, Brodie MJ. et al . Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009.  Epilepsia. 2010;  51 676-685
• 3 Coppola G, Grosso S, Franzoni E. et al . Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.  Eur J Neurol. 2011;  18 246-251
• 4 Glauser T, Kluger G, Sachdeo R. et al . Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.  Neurology. 2008;  70 1950-1958
• 5 Holmes GL, Zhao Q. Choosing the correct antiepileptic drugs: from animal studies to the clinic.  Pediatr Neurol. 2008;  38 151-162
• 6 Kluger G, Haberlandt E, Kurlemann G. et al . First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy.  Epilepsy Behav. 2010;  17 546-548
• 7 Manonmani V, Wallace SJ. Epilepsy with myoclonic absences.  Arch Dis Child. 1994;  70 288-290
• 8 Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline.  Epilepsy Res. 2006;  69 273-294
• 9 Tassinari CA BM, Thomas P. Epilepsy with myoclonic absences. In: Roger J BM, Dravet Ch, Dreifuss FE, Perret A, Wolf P ed, Epileptic syndromes in infancy, childhood and adolescence. 2nd ed. London: John Libbey; 1992: 151-160
• 10 Verrotti A, Greco R, Chiarelli F. et al . Epilepsy with myoclonic absences with early onset: a follow-up study.  J Child Neurol. 1999;  14 746-749
• 11 Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug.  Epilepsy Curr. 2010;  10 1-6
• 12 Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome.  Ann Pharmacother. 2010;  44 658-667

1 All authors have contributed equally.

Correspondence